The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its partnership with Wageningen Bioveterinary Research (WBVR) to advance WBVR’s vaccine candidate against Rift Valley fever (RVF) through a multi-site Phase...Read More
CR2O is a leading European clinical CRO, specialised in managing and operating early-stage infectious disease clinical trials. Artemis Bioservices is a specialty lab, evaluating viral vaccines and antiviral therapeutics, in...Read More
A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a...Read More
CR2O is happy to announce that the First-in-Human trial with Dyadic’s SARS-CoV-2-RBD vaccine candidate DYAI-100 has started in South Africa. Dyadic International Inc. is a global biotechnology company focused on...Read More
The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA consortium and which started this week, will assess...Read More
The clinical trial application of the LARISSA study is the first application submitted successfully by CR2O under the new European Clinical Trial Regulation (ECTR). The ECTR is the new regulation...Read More
Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD). Freya Pharma...Read More
CR2O is proud to announce today it will manage and further support the clinical and preclinical development of DYAI-100, Dyadic’s C1 produced SARS-CoV-2-S-RBD vaccine candidate. The first-in-human trial with DYAI-100...Read More
Dutch industry magazine Biotech NEWS and Life Sciences has profiled CR2O in their 2020 Winter edition. Biotech NEWS and Life Sciences is a national magazine reporting on trends and news within health...Read More
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.